Shape-shifting Molecule Can Trick Viruses Like Hepatitis C Into Mutating Themselves to Death

In order to understand the molecular mechanisms by which an anti-HIV medication induces fatal mutations in the virus’s genetic material, researchers at University of Chicago and the Massachusetts Institute of Technology are using a new spectroscopy method. Results from the study may support efforts for the development of next generation anti-viral treatments.

In order to adapt to environmental pressure viruses are able to rapidly mutate, a feature that makes viruses able to become resistant to anti-viral drugs. However, using a strategy called lethal mutagenesis, scientists have been able to develop therapeutic anti-viral agents for Hepatitis C, HIV and influenza. This approach is able to douse viruses by making their high mutation rates above an unbearable threshold. If they face too much mutation they are unable to their genetic material.

“They can’t replicate and so are quickly eliminated,” said Andrei Tokmakoff, the Henry G. Gale Distinguished Service Professor in Chemistry at UChicago in a recent news release. “In order to make this work, you need a stealth mutagen. You need something sneaky, something that the virus isn’t going to recognize as a problem.”

“We also have done nuclear magnetic resonance, which is very informative, but those studies were done in organic solvents that probably do not as accurately provide a view of what happens in cells as did the infrared studies done by the Tokmakoff group,” Essigmann said in the news release. The researchers designed lethally mutagenic molecules like KP1212 to look like biological DNA bases, the adenine-thymine, cytosine-guanine base pairs. “These analogs can bind to the wrong base partners and therefore lead to genetic mutations,” said the study’s lead author, Sam Peng in the news release.

KP1212 is a variation of cytosine, which usually pairs during replication with guanine. However, KP1212 induces mutations when it pairs with adenine. Results from previous studies have indicate that KP1212 indices mutations by shape shifting — converting into another molecular structure by relocating its hydrogen atoms on nitrogen and oxygen atoms, a process called tautomer.

In 1953, James Watson, SB’47, and Francis Crick proposed the tautomer hypothesis is based on the DNA’s double-helical structure. “The shuffled hydrogen positions in rare tautomers alter the hydrogen bonding patterns, resulting in incorrect base paring,” said Peng.

In contrast with traditional methods, the 2D infrared spectroscopy is able to distinguish between the normal and shape-shifted structures. In this news research the scientists measured the rapid shape shifting and found that it occurs under physiological conditions: in 20 billionths of a second.

In their experiments, the researchers thought that they were going to find only two dominant tautomers, however, they found more, as KP1212 can also accept an extra proton, giving it a positive charge at physiological levels of acidity making it possible to have more rearrangements and more tautomer structures. “The number of possibilities exploded,” Tokmakoff said.

The researchers also found that both the protonated and non-protonated forms eased the rate of viral mutation, even if the protonated form is absent the virus is still able to mutate, however, at a lower rate. “We found that under physiological pHs, KP1212 is significantly protonated and this protonated form induces even higher mutation rates, reaching approximately 50 percent,” Peng said. “KP1212 is about 20 percent of the way toward being an ideal therapeutic mutagen. The hints given us by the spectroscopy guide us toward even better mutagenic molecules,” Essigmann added.

Essigmann and Tokmakoff were able to fruitfully undertake one of the first 2D infrared spectroscopic studies of the therapeutic mechanism of an anti-viral drug “This is how basic research works,” Tokmakoff concluded. “This is how so often you get transitions from basic research to real applications. They can’t be predicted.”

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

Disclaimer:

Hepatitis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more